Morphic Holding, Inc. (MORF): Price and Financial Metrics


Morphic Holding, Inc. (MORF): $22.44

0.11 (+0.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MORF to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MORF POWR Grades


  • MORF scores best on the Sentiment dimension, with a Sentiment rank ahead of 69.35% of US stocks.
  • The strongest trend for MORF is in Value, which has been heading down over the past 179 days.
  • MORF ranks lowest in Momentum; there it ranks in the 12th percentile.

MORF Stock Summary

  • Morphic Holding Inc's stock had its IPO on June 27, 2019, making it an older stock than merely 7.98% of US equities in our set.
  • MORF's price/sales ratio is 79.66; that's higher than the P/S ratio of 97.23% of US stocks.
  • As for revenue growth, note that MORF's revenue has grown -55.96% over the past 12 months; that beats the revenue growth of only 2.81% of US companies in our set.
  • Stocks that are quantitatively similar to MORF, based on their financial statements, market capitalization, and price volatility, are NKTR, CARA, CCCC, MRTX, and FATE.
  • MORF's SEC filings can be seen here. And to visit Morphic Holding Inc's official web site, go to www.morphictx.com.

MORF Valuation Summary

  • In comparison to the median Healthcare stock, MORF's price/sales ratio is 421.59% higher, now standing at 59.2.
  • MORF's price/sales ratio has moved up 4.6 over the prior 27 months.
  • MORF's price/earnings ratio has moved down 15.7 over the prior 27 months.

Below are key valuation metrics over time for MORF.

Stock Date P/S P/B P/E EV/EBIT
MORF 2021-08-31 59.2 6.6 -37.3 -30.7
MORF 2021-08-30 58.1 6.5 -36.6 -30.0
MORF 2021-08-27 58.7 6.5 -37.0 -30.4
MORF 2021-08-26 58.2 6.5 -36.7 -30.1
MORF 2021-08-25 58.4 6.5 -36.8 -30.2
MORF 2021-08-24 57.1 6.4 -36.0 -29.4

MORF's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MORF has a Quality Grade of C, ranking ahead of 29.24% of graded US stocks.
  • MORF's asset turnover comes in at 0.114 -- ranking 252nd of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows MORF's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.114 1 -1.111
2021-03-31 0.150 1 -0.797
2020-12-31 0.199 1 -0.595
2020-09-30 0.170 1 -0.597
2020-06-30 0.079 1 -0.807
2020-03-31 0.072 1 -0.604

MORF Price Target

For more insight on analysts targets of MORF, see our MORF price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $100.50 Average Broker Recommendation 1.4 (Strong Buy)

MORF Stock Price Chart Interactive Chart >

Price chart for MORF

MORF Price/Volume Stats

Current price $22.44 52-week high $68.75
Prev. close $22.33 52-week low $21.20
Day low $21.56 Volume 242,800
Day high $22.86 Avg. volume 309,092
50-day MA $34.90 Dividend yield N/A
200-day MA $47.83 Market Cap 858.76M

Morphic Holding, Inc. (MORF) Company Bio


Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.


MORF Latest News Stream


Event/Time News Detail
Loading, please wait...

MORF Latest Social Stream


Loading social stream, please wait...

View Full MORF Social Stream

Latest MORF News From Around the Web

Below are the latest news stories about Morphic Holding Inc that investors may wish to consider to help them evaluate MORF as an investment opportunity.

Morphic Announces Corporate Highlights and Financial Results for the Full Year 2021

Presented positive Phase 1 data for MORF-057 Phase 2a trial in patients with ulcerative colitis scheduled to begin 1Q22; Phase 2b to commence mid-year Presented preclinical data from αvβ8 program at AACR and SITC demonstrating anti-tumor activity in checkpoint refractory cancer models Appointed Susannah Gray and Nisha Nanda, Ph.D., to Morphic Board of Directors Ended 2021 with $408 million in cash and equivalents, providing runway through year-end 2024 WALTHAM, Mass., Feb. 24, 2022 (GLOBE NEWSWI

Yahoo | February 24, 2022

Morphic Presents Positive MORF-057 Data in Oral Presentation at ECCO 2022

New preclinical data expand understanding of α4β7-expressing immune cells and MORF-057 dose response Data support ongoing clinical development program in IBD WALTHAM, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the Digital Oral Presentation of new data at the 17th Congress of European Crohn’s and Colitis Organisation (ECCO)

Yahoo | February 22, 2022

Bullish Morphic Holding, Inc. (NASDAQ:MORF) insiders filled their treasuries with US$28m worth of stock over last year

In the last year, multiple insiders have substantially increased their holdings of Morphic Holding, Inc. ( NASDAQ:MORF...

Yahoo | February 22, 2022

Do Hedge Funds Love Morphic Holding, Inc. (MORF)?

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F filings […]

Yahoo | January 12, 2022

Morphic Holding, Inc. (MORF) Upgraded to Buy: What Does It Mean for the Stock?

Morphic Holding, Inc. (MORF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | January 5, 2022

Read More 'MORF' Stories Here

MORF Price Returns

1-mo -25.55%
3-mo -43.86%
6-mo -55.90%
1-year -50.68%
3-year N/A
5-year N/A
YTD -52.64%
2021 41.22%
2020 95.51%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4647 seconds.